Literature DB >> 27847310

Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors.

Doriane Lorendeau1, Gianmarco Rinaldi1, Ruben Boon2, Pieter Spincemaille3, Kristine Metzger1, Christian Jäger4, Stefan Christen1, Xiangyi Dong4, Sabine Kuenen5, Karin Voordeckers6, Patrik Verstreken5, David Cassiman7, Pieter Vermeersch8, Catherine Verfaillie2, Karsten Hiller4, Sarah-Maria Fendt9.   

Abstract

Mutations in succinate dehydrogenase (SDH) are associated with tumor development and neurodegenerative diseases. Only in tumors, loss of SDH activity is accompanied with the loss of complex I activity. Yet, it remains unknown whether the metabolic phenotype of SDH mutant tumors is driven by loss of complex I function, and whether this contributes to the peculiarity of tumor development versus neurodegeneration. We addressed this question by decoupling loss of SDH and complex I activity in cancer cells and neurons. We found that sole loss of SDH activity was not sufficient to recapitulate the metabolic phenotype of SDH mutant tumors, because it failed to decrease mitochondrial respiration and to activate reductive glutamine metabolism. These metabolic phenotypes were only induced upon the additional loss of complex I activity. Thus, we show that complex I function defines the metabolic differences between SDH mutation associated tumors and neurodegenerative diseases, which could open novel therapeutic options against both diseases.
Copyright © 2016 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (13)C metabolic flux analysis; 3-nitropropionic acid (PubChem CID: 1678); Ataxia; Atpenin A5 (PubChem CID: 54676868); CB-839 (PubChem CID: 71577426); Complex I of the electron transport chain; Gastrointestinal stromal tumors; Leigh syndrome; Leukodystrophy; Mitochondrial respiration; Paraganglioma; Pyruvate carboxylase; Reductive glutamine metabolism; SDH mutations; Succinate dehydrogenase; rotenone (PubChem CID: 6758)

Mesh:

Substances:

Year:  2016        PMID: 27847310     DOI: 10.1016/j.ymben.2016.11.005

Source DB:  PubMed          Journal:  Metab Eng        ISSN: 1096-7176            Impact factor:   9.783


  24 in total

1.  2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer.

Authors:  Arnaud Blomme; Catriona A Ford; Ernest Mui; Rachana Patel; Chara Ntala; Lauren E Jamieson; Mélanie Planque; Grace H McGregor; Paul Peixoto; Eric Hervouet; Colin Nixon; Mark Salji; Luke Gaughan; Elke Markert; Peter Repiscak; David Sumpton; Giovanny Rodriguez Blanco; Sergio Lilla; Jurre J Kamphorst; Duncan Graham; Karen Faulds; Gillian M MacKay; Sarah-Maria Fendt; Sara Zanivan; Hing Y Leung
Journal:  Nat Commun       Date:  2020-05-19       Impact factor: 14.919

2.  HIF-1α metabolically controls collagen synthesis and modification in chondrocytes.

Authors:  Steve Stegen; Kjell Laperre; Guy Eelen; Gianmarco Rinaldi; Peter Fraisl; Sophie Torrekens; Riet Van Looveren; Shauni Loopmans; Geert Bultynck; Stefan Vinckier; Filip Meersman; Patrick H Maxwell; Jyoti Rai; MaryAnn Weis; David R Eyre; Bart Ghesquière; Sarah-Maria Fendt; Peter Carmeliet; Geert Carmeliet
Journal:  Nature       Date:  2019-01-16       Impact factor: 49.962

Review 3.  New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.

Authors:  David Taïeb; Karel Pacak
Journal:  Trends Endocrinol Metab       Date:  2017-08-31       Impact factor: 12.015

4.  Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth.

Authors:  Shauni Lien Geeraerts; Kim Rosalie Kampen; Karin Thevissen; Kim De Keersmaecker; Gianmarco Rinaldi; Purvi Gupta; Mélanie Planque; Nikolaos Louros; Elien Heylen; Kaat De Cremer; Katrijn De Brucker; Stijn Vereecke; Benno Verbelen; Pieter Vermeersch; Joost Schymkowitz; Frederic Rousseau; David Cassiman; Sarah-Maria Fendt; Arnout Voet; Bruno P A Cammue
Journal:  Mol Cancer Ther       Date:  2020-11-17       Impact factor: 6.261

5.  Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.

Authors:  Hanumantha Rao Madala; Iiro Taneli Helenius; Wen Zhou; Evanna Mills; Yiyun Zhang; Yan Liu; Ana M Metelo; Michelle L Kelley; Surendra Punganuru; Kyung Bo Kim; Benjamin Olenchock; Eugene Rhee; Andrew M Intlekofer; Othon Iliopoulos; Edward Chouchani; Jing-Ruey Joanna Yeh
Journal:  Cancer Res       Date:  2020-07-10       Impact factor: 12.701

6.  In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition.

Authors:  Gianmarco Rinaldi; Erica Pranzini; Joke Van Elsen; Dorien Broekaert; Cornelius M Funk; Mélanie Planque; Ginevra Doglioni; Patricia Altea-Manzano; Matteo Rossi; Vincent Geldhof; Shao Thing Teoh; Christina Ross; Kent W Hunter; Sophia Y Lunt; Thomas G P Grünewald; Sarah-Maria Fendt
Journal:  Mol Cell       Date:  2020-12-18       Impact factor: 19.328

7.  Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells.

Authors:  Ilaria Elia; Dorien Broekaert; Stefan Christen; Ruben Boon; Enrico Radaelli; Martin F Orth; Catherine Verfaillie; Thomas G P Grünewald; Sarah-Maria Fendt
Journal:  Nat Commun       Date:  2017-05-11       Impact factor: 14.919

Review 8.  Mitochondrial Deficiencies in the Predisposition to Paraganglioma.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Anne-Paule Gimenez-Roqueplo; Judith Favier
Journal:  Metabolites       Date:  2017-05-04

9.  Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency.

Authors:  Melissa Vos; Ann Geens; Claudia Böhm; Liesbeth Deaulmerie; Jef Swerts; Matteo Rossi; Katleen Craessaerts; Elvira P Leites; Philip Seibler; Aleksandar Rakovic; Thora Lohnau; Bart De Strooper; Sarah-Maria Fendt; Vanessa A Morais; Christine Klein; Patrik Verstreken
Journal:  J Cell Biol       Date:  2017-01-30       Impact factor: 10.539

10.  Is There a Therapeutic Window for Metabolism-Based Cancer Therapies?

Authors:  Sarah-Maria Fendt
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.